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MALARIA IN THE BLOOD SUPPLY IN AFRICA: IS IT A PROBLEM?

Although international policies recommend that blood for transfusion should be screened for transfusion-transmitted infections, malaria screening is not carried out in most malaria-endemic countries in sub-Saharan Africa (SSA). There are several reasons why this recommendation may not have been implemented. Serological screening tests are unhelpful in areas where malaria is endemic as most of the population have anti-malaria antibodies. There is a lack of evidence to indicate which malaria screening methods are effective for use by transfusion services in malaria-endemic countries in SSA. This is important because alternative malaria screening tests, such as microscopy, ELISA or rapid tests, are not sensitive enough to detect low levels of parasites in potential blood donors. 

Critical shortages of blood are common; for example in SSA 26% of maternal haemorrhage deaths between 1970 and 2007 were due to lack of blood for transfusion.  Blood transfusion services are understandably reluctant to implement any policy which is likely to exacerbate blood shortages. A review of the literature indicated that 10% of 33,029 blood donors in SSA were positive for malaria. Rejection of all these malaria-positive donors would undoubtedly have a major impact on the blood supply. A further complication is that the prevalence of malaria varies widely across Africa from 0.7% in Kenya to 55.0% in Nigeria making it difficult to devise a single policy that is appropriate for the whole continent. 

Even more fundamental is the question of whether or not the transfusion of low levels of malaria parasites to recipients living in endemic areas has adverse clinical consequences and therefore whether a policy recommending malaria screening is justified at all. Prior to the introduction of artemisinin combination therapy (ACT), pre-emptive treatment of transfusion recipients with chloroquine was cost effective. Given the higher cost of ACT’s and the need to prevent the spread and rapid development of resistance, screening policies will become invaluable. Despite the considerable costs associated with implementing a malaria-screening policy for blood transfusion, we have not been able to find any studies from SSA that investigated the clinical outcomes of receiving malaria-infected blood. We urgently need to fill these gaps in our knowledge about the benefits, risks and processes for screening blood for malaria so that appropriate and feasible policies about screening blood for malaria can be developed for the SSA region. 



